Clinical Studies with Indian COVID 19 Vaccines Over 100 experts trained nations

Over 100 experts from friendly nations have been trained for clinical studies with Indian COVID-19 vaccines
Image source: AP

Over 100 experts from friendly nations have been trained for clinical studies with Indian COVID-19 vaccines

So far, over 100 experts from friendly neighbors have been trained to bolster capacities in their countries to enable Phase 3 clinical trials of Indian COVID-19 vaccines, a senior biotechnology official said on Wednesday. Alka Sharma, Advisor to the Department of Biotechnology, spoke at a webinar organized by the Indian Industry Association about the Clinical Trials Promotion Initiative (PACT) being carried out in collaboration with the Ministry of Foreign Affairs.

“… The PACT is on the initiative of the Department of Biotechnology and the Department of Foreign Affairs to strengthen capacities to facilitate Phase 3 clinical trials of Indian COVID vaccines in friendly neighboring countries,” she said.

Two training modules have so far been successfully completed as part of this initiative.

“More than 100 participants from Afghanistan, Bhutan, Maldives, Mauritius, Nepal and Sri Lanka took part in this training program,” she said.

The plan is to have the next round of the training program with more participants, she added.

There are currently 30 groups actively involved in the development of the coronavirus vaccine.

Six vaccines are in various stages of clinical trials, four of which are being developed locally, she said.

Sharma said Bharat Biotech’s clinical traces are in Phase 3 while that developed by Zydus Cadila is in Phase 2 of the clinical trial.

Biological E’s vaccine candidate is in Phase 1 clinical trials, while Gennova Biopharmaceuticals is currently receiving regulatory approvals at various levels.

The Serum Institute of India (SII) is also conducting Phase 2 and 3 clinical trials of the Oxford-Astrazeneca vaccine.

Similarly, Dr. Reddy is conducting phase 2 and 3 clinical trials for the Russian Sputnik V vaccine, she said.

ALSO READ | Bharat Biotech’s Covaxin is “well tolerated” in all dose groups; no serious adverse events in phase 1 studies

Latest India News

Source